What factors should I consider when comparing Nippon India Pharma Fund - Direct (G) vs Quant Mid Cap Fund - Direct (G)?

When comparing Nippon India Pharma Fund - Direct (G) vs Quant Mid Cap Fund - Direct (G), consider factors such as historical performance, expense ratios, investment strategy, risk level, and the fund manager's credibility. Moreover, look at asset allocation and how each fund fits your investment goals.

Can I invest in Nippon India Pharma Fund - Direct (G) and Quant Mid Cap Fund - Direct (G) simultaneously?

Yes, you can invest in both Nippon India Pharma Fund - Direct (G) and Quant Mid Cap Fund - Direct (G) at the same time. This can help diversify your portfolio and balance risk, provided the fund manager's investment strategies streamline each other.

What does the portfolio turnover ratio tell us when comparing Nippon India Pharma Fund - Direct (G) and Quant Mid Cap Fund - Direct (G)?

While comparing Nippon India Pharma Fund - Direct (G) and Quant Mid Cap Fund - Direct (G), the portfolio turnover ratio indicates how frequently assets within the fund are bought and sold. A high turnover may lead to higher transaction costs and tax implications, while a low turnover ratio indicates a buy-and-hold strategy.

Can I switch between Nippon India Pharma Fund - Direct (G) and Quant Mid Cap Fund - Direct (G) if needed?

Yes, you can typically switch between Nippon India Pharma Fund - Direct (G) and Quant Mid Cap Fund - Direct (G), subject to the fund's policies and any applicable fees. It is important to consider potential tax implications and the timing of your switch.

Can I compare Nippon India Pharma Fund - Direct (G) and Quant Mid Cap Fund - Direct (G) based on their dividend payout?

Yes, you can compare Nippon India Pharma Fund - Direct (G) and Quant Mid Cap Fund - Direct (G) based on their dividend payouts. Look at dividends profit, consistency, and growth, as these factors can influence your overall return on investment.

Compare Nippon India Pharma Fund - Direct (G) vs Quant Mid Cap Fund - Direct (G) Online

Home

Mutual Funds

Compare Mutual Funds

Nippon India Pharma Fund - Direct (G) vs Quant Mid Cap Fund - Direct (G)

Nippon India Pharma Fund - Direct (G)

7.4%

Quant Mid Cap Fund - Direct (G)

3.73%

Loading chart...

About Fund

Custodian

Deutsche Bank AG

Registrar

Karvy Computershare Pvt. Ltd.

Custodian

HDFC Bank Limited

Registrar

In House Registrar

Fund Details

Risk

Very High Risk

Min SIP Amount

5000

Fund Size

9044.23

Expense Ratio

1.12

NAV

634.5023

Launch Date

January 1, 2013

Exit Load

Risk

Very High Risk

Min SIP Amount

5000

Fund Size

8138.18

Expense Ratio

1.47

NAV

250.1527

Launch Date

January 1, 2013

Exit Load

Risk

Very High Risk

Min SIP Amount

5000

Fund Size

9044.23

Expense Ratio

1.12

NAV

634.5023

Launch Date

January 1, 2013

Exit Load

Risk

Very High Risk

Min SIP Amount

5000

Fund Size

8138.18

Expense Ratio

1.47

NAV

250.1527

Launch Date

January 1, 2013

Exit Load

14.01 %

19.35 %

7.4 %

16.96 %

14.05 %

3.73 %

Fund Manager

Sailesh Raj Bhan

Qualification

MBA (Finance), CFA.

Experience

Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.

Fund Manager

Archit Singhal

Qualification

B.COM., MBA., CFA.,

Experience

He worked as Research Associate in Institutional Equities with Prabhudas Lilladher and as Research Analyst with Globe Capital Market Ltd.

Fund Manager

Sandeep Tandon

Qualification

MBA

Experience

Sandeep Tandon is the founder of the quant group and has 20 years of experience in the financial services industry. Sandeep's previous stints include a key role in setting up the equity derivatives desk at ICICI Securities as vice president. He started his career with the Economic Times Research Bureau, a research wing of the leading financial daily of India, The Economic Times. He later joined IDBI Asset Management (now Principal Asset Management), and was part of the core team that initialized asset management, playing a key role in devising, conceptualizing and marketing one of India's most successful mutual schemes: IDBI I-NITS 95.

Fund Manager

Sanjay Arora

Qualification

ACA,Grad CWA

Experience

He has more than 18 years of experience in equity market. Tenure for scheme managment Since 25.07.2013.

Fund Manager

Sanjeev Sharma

Qualification

PGDBA(Fin.), M.com and CerTM (Treasury & Forex Risk)

Experience

He has total work experience of 18 years including 13 years of experience in the financial market. He specializes in identifying crucial inflexion points in securities.

Nippon India Pharma Fund - Direct (G) vs Quant Mid Cap Fund - Direct (G)

Nippon India Pharma Fund - Direct (G)

7.4%

Quant Mid Cap Fund - Direct (G)

3.73%

About Fund

Fund Details

Get your FAQs right